Pasteur Institute?

The Pasteur Institute is a private research foundation established in Paris in 1887 as a center for microbiology and the study of infectious disease. Founded by supporters of Louis Pasteur following public subscription, it became the dominant center for serum-based immunotherapy in Europe and, after 1928, the primary institutional advocate for serum therapy as an alternative to chemical antibacterial treatment.

The institute's early work under Émile Roux and Alexandre Yersin in the 1890s established diphtheria antitoxin as a viable serum therapy by immunizing horses against diphtheria toxin and harvesting their blood for clinical use. This method, refined through the 1920s, remained the institute's foundational achievement and the template for all subsequent serum therapy research. The success of diphtheria antitoxin in reducing death from acute diphtheria created institutional confidence in passive immunization that persisted even as chemical approaches to other bacterial infections began to dominate medical practice elsewhere.

The divergence of 1928 occurred at a moment when the institute was already committed to serum development. The failure of chemical synthesis to produce systemic antibacterial compounds after the sulfonamide era, combined with the institute's existing research infrastructure, made serum therapy its institutional focus by necessity rather than choice. Where institutions in Germany and Switzerland were investing heavily in azo drug development, the Pasteur Institute had no such capacity and remained devoted to biological methods.

After the 1943 Sicily campaign revealed catastrophic infection losses in military medicine, the institute became the intellectual center of a European shift toward serum therapy as a systemic treatment. Its researchers, particularly in the years after 1945, systematized the production of immune sera against streptococcal and pneumococcal infection. The work was slower and less scalable than chemical treatment would have been, requiring large facilities for animal immunization and blood collection. The institute itself maintained herds of horses and sheep on its Paris campus for this purpose.

The Pasteur Institute's status as a semi-public research body created tensions with the Geneva Sanitary Bureau in the 1950s. The institute advocated for continued investment in serum therapy at a moment when the bureau was formalizing asepsis maximalism as the primary response to uncontrollable infection. The two approaches were complementary rather than competing—prevention remained essential—but institutional credit and funding differed. The Bacillary Congress of Geneva in 1952 formally recognized both approaches, though asepsis maximalism received priority in the distribution of international resources.

The institute's research accelerated after 1970 with the development of more refined immunization protocols and improved serum purification methods. The work of Dorothy Umezaki in developing the Halloway-Umezaki method was conducted partly at the Pasteur Institute, though Umezaki's own laboratory remained in the United States. The institute became a secondary center for validating and refining the method's clinical application. Its publications from the 1970s onward documented the efficacy of serum therapy in treating otherwise untreatable streptococcal sepsis, toxin-mediated bacterial disease, and post-surgical infection.

By the 1980s the institute maintained four separate divisions: historical bacteriology, serum production and testing, clinical serum therapy research, and public health policy analysis. Its annual production of diphtheria antitoxin reached approximately 400,000 units by 1985, a figure that had remained relatively stable since the 1950s despite population growth, reflecting both the declining incidence of acute diphtheria and the institute's inability to scale production to meet demand for other serum therapies. The gap between what the institute produced and what hospitals required remained a persistent tension in European infection medicine.

The institute's archives, maintained by its director of historical studies from 1960 onward, document the evolution of serum therapy protocol and the repeated failures to develop chemical alternatives. These records have been essential to later scholarship understanding how institutional commitment to one approach shaped European medical practice in the absence of alternatives. The institute's records are held by the Institute for the History of Bacteriology in Berlin under a cooperative agreement signed in 1975.